Membranous Nephropathy
Fig.1 Pathogenic mechanisms and related biomarkers in lupus nephritis. (Renaudineau, Y., et al., 2023)
Membranous nephropathy is a kidney disease characterized by the thickening of the glomerular basement membrane, which leads to the leakage of protein into the urine. Our company stands at the forefront of innovation in the field of rare diseases, and our experience in diagnostics and therapy development sets us apart in delivering comprehensive services for researchers.
Overview of Membranous Nephropathy
Membranous nephropathy is a rare kidney disease with an incidence of approximately 10-12 cases per million per year. The disease is characterized by the dysfunction of the glomerular basement membrane (GBM), which plays a crucial role in filtering waste and excess fluids from the blood. The long-term prognosis of membranous nephropathy is varied, with around one-third of individuals progressing to renal failure if persistent proteinuria is left uncontrolled.
Pathogenesis of Membranous Nephropathy
The pathogenesis of membranous nephropathy involves the formation of immune deposits on the GBM. In primary cases, these immune deposits contain antibodies that target a protein known as phospholipase A2 receptor (PLA2R) present on the surface of glomerular podocytes. The binding of these antibodies to PLA2R leads to the activation of complement and the formation of immune complexes on the GBM, triggering inflammation and disrupting the normal filtration function of the glomeruli.
Fig.2 Pathogenesis of membranous nephropathy. (Liu, Q., et al., 2022)Biomarkers Development of Membranous Nephropathy
Various biomarkers are associated with membranous nephropathy, aiding in the diagnosis, prognosis, and monitoring of the disease. These biomarkers provide valuable insights that can guide therapy decisions and disease management strategies.
Fig.3 Biomarkers of membranous nephropathy.Therapeutics Development of Membranous Nephropathy
Immunosuppressive Therapy
Supportive Therapy
Our Services
Our company has cutting-edge technologies and innovative ideas, with our animal models and therapeutic development platform can support you in uncovering potential therapeutic targets and developing innovative therapy modalities.
Therapy Development Platforms
Animal Models of Membranous Nephropathy
Animal models play a crucial role in studying the pathogenesis, mechanisms, and potential therapeutics for membranous nephropathy. Our company offers a variety of animal models to help you investigate various aspects of membranous nephropathy, such as its pathogenesis, biomarkers, and potential therapeutic interventions.
Induced Models
The induced model of membranous nephropathy involves the administration of substances such as toxins, drugs, or antibodies to animals to replicate the disease in a controlled laboratory setting.
Optional Models:
- C-BSA-induced model
- PM2.5-induced model
- ASD-4-induced model
- More
Genetically Engineered Models
Genetic engineering animal models of membranous nephropathy involves the genetic manipulation of animals to create a specific mutation or overexpression of genes associated with the disease.
Optional Models:
- PLA2R1 transgenic model
- THSD7A transgenic model
- More
Our commitment to addressing the unmet needs of the rare diseases field drives us to provide comprehensive support to researchers, including pharmacokinetic studies and drug safety evaluation. If you are interested in learning more about our services and how we can support your research endeavors, please do not hesitate to reach out to us for further information.
References
- Liu, Qiuying et al. "Novel Biomarkers in Membranous Nephropathy." Frontiers in immunology 13 (2022): 845767.
- Dantas, Márcio et al. "Membranous nephropathy." Jornal brasileiro de nefrologia 45.2 (2023): 229-243.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.